Linnea

Linnea is a Swiss-based company specializing in the extraction of plant-based active ingredients, nutraceutical for the pharmaceutical, nutraceutical, and cosmetic industries. Formerly a joint venture between Ipsen and Schwabe, Linnea benefits from over 40 years of expertise in the extraction of high-quality plant substances. These ingredients are used in therapeutic, preventive, and cosmetic applications.

Linnea’s portfolio of 10 ingredients includes a diverse range of high-quality products taking into account the minimization of the production environmental impact. The company is GMP-certified (Good Manufacturing Practices), ensuring that all its products meet the highest pharmaceutical quality standards and regulatory requirements.

Since 2016, Linnea has also been a pioneer in the medical cannabinoids sector, positioning itself as a key player in this rapidly growing market.

Linnea is now benefiting from the support of Vivalto Partners to accelerate its international development and further diversify its product portfolio, with a particular focus on sustainable and natural solutions. Linnea will continue to operate independently, with its management team being significantly invested in the capital.

« This acquisition represents an exciting new chapter for Linnea and the significant investment from management is a testimony of our commitment to the company’s success. We look forward to working with Vivalto Partners to continue building on our strong portfolio of botanical extracts and isolates, particularly in the medical cannabinoids market, and semi-synthesis APIs derived from botanicals. Our goal is to accelerate portfolio expansion and deploy into new markets. »

Susanne Caspar, CEO of Linnea